TMCnet - World's Largest Communications and Technology Community



Research and Markets: Global and Chinese Monoclonal Antibody Industry Report, 2013-2017
[January 07, 2014]

Research and Markets: Global and Chinese Monoclonal Antibody Industry Report, 2013-2017

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Global and Chinese Monoclonal Antibody Industry Report, 2013-2017" report to their offering.

Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period. Thanks to robust market demand, approval of new products and new indications as well as launch of monoclonal antibody generic drugs, the global monoclonal antibody market size will ascend by more than 12% in 2013-2017, hitting USD141 billion in 2017.

Driven by enhanced economic level, expanded scope of medical insurance reimbursement, as well as lower prices incurred by intensified competition, Chinese monoclonal antibody market is expected to continue to grow significantly. In 2013-2017, Chinese monoclonal antibody market will grow at 35%, sharing 21.5% of the global monoclonal antibody market in 2017 (9.5% in 2012).

The global monoclonal antibody industry is still dominated by European and American companies, especially, important monoclonal antibody product are mainly produced by Roche (Genentech), Amgen, AbbVie (Abbott), Johnson & Johnson and other companies. In 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) and Trastuzumab (Roche) stemmed from the above four companies. The global sales (including the sales of third parties) of these six monoclonal antibody agents totaled USD45 billion, accounting for 57.7% of the global.

Propelled by the optimistic market prospect, advancement of monoclonal antibody technologies and the upcoming patent expiration of several key monoclonal antibody agents, the research and industrialization of monoclonal antibody agents has become a global investment highlight, wherein the future market competition will be evident.

Key Topics Covered

1 Overview of Monoclonal Antibody Industry

1.1 Definition

1.2 Classification

1.3 Technological Development

2 Overview of Global Monoclonal Antibody Industry

2.1 Status Quo

2.2 Market Size

2.3 Competition Pattern

2.4 Development Prospect and Prediction

3 Chinese Monoclonal Antibody Market

3.1 Status Quo

3.2 Market Size

3.3 Market Segments

3.4 Competition Pattern

3.5 Development Prospect

4 Key Foreign Monoclonal Antibody Agent Enterprises

5 Key Chinese Monoclonal Antibody Agent Enterprises

6 Summary and Forecast

6.1 Comparison between Domestic and Foreign Companies

6.2 Market Forecast

Companies Mentioned

- AbbVie

- Amgen

- Beijing Biotech Pharmaceutical

- Beijing SL Pharmaceutical

- Chengdu Huasun Group

- Huahai Pharmaceutical

- Johnson & Johnson

- Merck


- Roche Pharmaceuticals

- Shanghai CP GuoJian Biotech Academy

- Shanghai CP Guojian Pharmaceutical

- Shanghai Fosun Pharmaceutical (Group)

- Shanghai Guosheng Pharmaceutical

- Shanghai Lansheng States Kin Pharmaceutical

- Shanghai Medipharm Biotech

- Shanghai Zhangjiang Biotech

- Shenzhen Main Luck Pharmaceuticals

- Yunnan Walvax Biotechnology

- Zhejiang Hisun Pharmaceutical

For more information visit

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy